3SBio Inc.
1530
Classificação em ações
#3650
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
Preço da ação
$1.85
Última sincronização: 2026-10-16
Valor de mercado
$4.63B
Variação (1 dia)
0.77%
Variação (1 ano)
-48.83%
País
CN
Negociar 3SBio Inc. (1530)
Categoria
Healthcare
Margem Operacional de 3SBio Inc. (1530)
Margem Operacional em October 2026 TTM: 61.16%
De acordo com os relatórios financeiros mais recentes e o preço das ações da 3SBio Inc., a margem operacional atual (TTM) é 61.16%. No final de 2023, a margem operacional era 31.45%.
Histórico da Margem Operacional da 3SBio Inc. de 2012 a 2026
Margem Operacional no final de cada ano
| Ano | Margem Operacional | Alterar |
|---|---|---|
| 2026 (TTM) | 61.16% | 110.32% |
| 2024 | 29.08% | -7.54% |
| 2023 | 31.45% | 4.24% |
| 2022 | 30.17% | 5.42% |
| 2021 | 28.62% | 9.40% |
| 2020 | 26.16% | 4.14% |
| 2019 | 25.12% | -20.25% |
| 2018 | 31.50% | 1.81% |
| 2017 | 30.94% | -4.77% |
| 2016 | 32.49% | 13.56% |
| 2015 | 28.61% | -14.80% |
| 2014 | 33.58% | 5.46% |
| 2013 | 31.84% | 57.08% |
| 2012 | 20.27% | 0.00% |
Margem Operacional de empresas semelhantes ou concorrentes
| Empresa | Margem Operacional | Diferença na Margem Operacional | País |
|---|---|---|---|
| 38.59% | -99.37% |
US
|
|
| -149.01% | -102.44% |
US
|
|
| 25.57% | -99.58% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.53% |
NL
|
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.